Prevail Therapeutics
New York, United States· Est. 2017
Advancing gene therapy for neurodegenerative and rare diseases.
Private Company
Total funding raised: $287M
About
Advancing gene therapy for neurodegenerative and rare diseases.
RNA & Gene Therapy
Funding History
3Total raised:$287M
IPO$150MJul 10, 2020
Series B$62MJun 15, 2019
Series A$75MJan 15, 2018